CurrentCapital BluecrossPolicy MP 2.176

Self-Administered Medications

Defines medications considered appropriate for self-administration and states that those medications are generally excluded from the medical benefit for Commercial products and must be obtained via the pharmacy benefit.

Policy Summary

PayerCapital Bluecross

PolicySelf-Administered Medications

Policy CodePolicy MP 2.176

Change TypeNo material changes

Effective DateJan 1, 2026

Next Review Date

Key ActionMembers must use the pharmacy benefit to obtain self-administered medications when a pharmacy benefit exists.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Commercial onlyapplies to

All oral drugs excludedoral medications excluded

Attachment A listedattachment A

01/01/2026effective

Coverage Criteria — Self-Administered Medications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General exclusion of self-administered medications from medical benefit

Covered/Not covered stance

Primary coverage rule: Medications designated as 'self-administered' are not eligible for reimbursement under the medical benefit for Commercial products; members must use the pharmacy benefit if available.

Route of administration is irrelevant; exceptions only as mandated by law (e.g., insulin, medications required for treatment of diabetes, or emergent treatments).

Provider administration reimbursement limitation

Exception for provider administration

Administration service only: If an eligible provider must administer a self-administered medication, only the administration service may be eligible for reimbursement under the medical benefit (the drug itself remains the responsibility of the pharmacy benefit).

Providers should document the clinical rationale for in‑office administration and that the patient or caregiver cannot safely self‑administer if claiming administration under the medical benefit.

Coding — Attachment A (HCPCS / J-codes)

Attachment A — Listed self-administered medications and HCPCS/J-codesHCPCSNot Covered

Q5145	Abrilada (adalimumab-afzb)
J9216	Actimmune (interferon gamma-1b)
J3031	Ajovy (Fremanezumab-vfrm) / J3590 alternate
A7023	Alzair Allergy Blocker (Hydroxypropyl methylcellulose)
J1652	Arixtra (fondaparinux)
J1830	Betaseron and other listed items (multiple mappings across Attachment A)
Q5143	Cyltezo (Adalimumab-adbm)
J0270	Caverject/Edex/Muse (alprostadil)
J0275	Caverject Impulse (alprostadil)
J1595	Copaxone (glatiramer acetate)

1–10 of 31

1/4

Provider Actions and Billing Guidance

Denial Risk

Medical benefit denial risk for self‑administered drugs

Claims submitted to the medical benefit for medications that are designated as self‑administered are at high risk of denial. Self‑administered medications are expected to be billed and reimbursed under the member's pharmacy benefit (whether through Capital BlueCross or another insurer).

Affected items: See Attachment A for specific medications and coding guidance.
All oral medications are excluded from the medical benefit.

Documentation Required

Document administration rationale

If an eligible provider must administer a medication that is otherwise designated as self‑administered, the provider must document the clinical rationale for administration in the medical record. Only the administration service (not the drug) may be considered for reimbursement under the medical benefit when adequate documentation justifies that provider administration was necessary.

Documentation should include reason administration was required, clinical assessment, and attempts to use pharmacy benefit when available.
Decision must align with member benefit and any applicable legal mandates (e.g., insulin for diabetes if mandated).

Prior Authorization

Pharmacy benefit use required

Members are required to obtain self‑administered medications through the pharmacy benefit when a pharmacy benefit exists. Providers should verify member benefit and direct the member to the pharmacy or preferred vendor for drug acquisition; prior authorization or other pharmacy requirements listed in Attachment A and the member benefit may apply.

Pharmacy benefit use required when available.
Check Attachment A and member benefit for specific coding and prior authorization requirements.

Background

For the purposes of this policy, self-administered medications are those identified as medically appropriate for safe and effective administration by the patient or a caregiver without medical supervision; the route of administration (oral, inhaled, subcutaneous, topical, or occasionally intramuscular) is irrelevant to the designation. Providers should ensure patients and caregivers receive appropriate education and instructions for safe administration when these products are prescribed.

This policy applies to Commercial products and documents that self-administered medications are generally excluded from the medical benefit; when an administration by an eligible provider is clinically necessary, only the administration service (not the drug) may be eligible for medical benefit reimbursement, and providers should document the clinical rationale for in‑office administration.

Definitions

Self‑administered medication — definition and benefit designation

Definition'Self-administered' medications are those identified as medically appropriate for administration by a patient or caregiver, safely and effectively, without medical supervision; the route of administration is irrelevant.

Administration routes includedMay be administered orally, subcutaneously, topically, by inhalation, or occasionally by intramuscular injection.

Prescriber requirementMust be prescribed by an eligible healthcare provider to be designated self-administered.

Evidence requirementMedication must be identified in published literature (e.g., Medicare guidelines, FDA recommendations) as safe and effective for self-administration with or without instruction or initial observation.

Benefit designation (most actionable)Medications designated as self-administered are not eligible for reimbursement under the medical benefit for Commercial products and must be obtained through the pharmacy benefit (highlighted).

Provider administration exceptionIf an eligible provider must administer a self-administered medication, only the administration service may be eligible for reimbursement under the medical benefit; the drug remains the pharmacy benefit responsibility.

Step	Requirement
1	Members must use their pharmacy benefit to obtain self‑administered medications when a pharmacy benefit exists; medications should be acquired through a pharmacy provider or preferred vendor.

Site of Care

Note

Self‑administered medications intended for home/outpatient use

Treat self‑administered medications as intended for patient or caregiver administration in home or outpatient settings and obtain them via the pharmacy benefit rather than the medical benefit.

Route of administration is irrelevant to designation
Intended setting: home or outpatient

Biosimilars and Specific Agents

Billing Rule

Humira (adalimumab) and listed biosimilars in Attachment A

Refer to Attachment A for the Humira (adalimumab) reference drug and its listed biosimilars (Hulio, Yuflyma, Simlandi, Cyltezo, Abrilada, Idacio) with assigned HCPCS/Q‑codes; these products are included in the self‑administered medication table.

Biosimilars listed include Hulio, Yuflyma, Simlandi, Cyltezo, Abrilada, Idacio
Assigned HCPCS/Q codes are shown in Attachment A